Financials data is unavailable for this security.
View more
Year on year Integrated Biopharma Inc had relatively flat revenues (50.67m to 50.32m), though the company grew net income from a loss of 34.00k to a gain of 112.00k. A reduction in the selling, general and administrative costs as a percentage of sales from 7.78% to 7.22% was a component in the net income growth despite flat revenues.
| Gross margin | 7.72% |
|---|---|
| Net profit margin | 0.22% |
| Operating margin | 0.50% |
| Return on assets | 0.43% |
|---|---|
| Return on equity | 0.59% |
| Return on investment | 0.55% |
More ▼
Cash flow in USDView more
In 2024, Integrated Biopharma Inc increased its cash reserves by 27.43%, or 361.00k. The company earned 943.00k from its operations for a Cash Flow Margin of 1.87%. In addition the company used 553.00k on investing activities and also paid 29.00k in financing cash flows.
| Cash flow per share | 0.0143 |
|---|---|
| Price/Cash flow per share | 22.40 |
| Book value per share | 0.6391 |
|---|---|
| Tangible book value per share | 0.6391 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.92 |
|---|---|
| Quick ratio | 1.08 |
| Total debt/total equity | 0.0004 |
|---|---|
| Total debt/total capital | 0.0004 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 790.57%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| EPS growth(5 years) | -42.26 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 331.58 |
